BioNexus Gene Lab Corp. completes 1-for-12 reverse stock split effective July 20, 2023

BioNexus Gene Lab Corp

Reverse stock split at 1-for-12 ratio effective July 20, 2023; prior 1-for-10 plan amended.
No fractional shares; odd lots under 100 shares rounded up to nearest whole share or 100 shares.
Authorized shares unchanged at 300M common and 30M preferred; par value unchanged.
New CUSIP following split: 090628207.
Split approved by stockholders and board on May 8, 2023; FINRA announced July 19, 2023.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

BioNexus Gene Lab Corp: Reverse stock split (1-for-12) effected by filing an Article of Amendment to the Articles of Incorporation (effective 2023-07-19).

Change: charter amendment
Effective: 2023-07-19

Exact text from the filing

On July 19, 2023, the Financial Industry Regulatory Authority announced the Revised Reverse Stock Split. On July 20, 2023, the Revised Reverse Stock Split went effective.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

BioNexus Gene Lab Corp filing history →

Source: SEC EDGAR

accession 0001477932-23-005435

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.